LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Sanofi

Open

47.18 2.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

46.08

Max

47.27

Belangrijke statistieken

By Trading Economics

Inkomsten

2.1B

3.9B

Verkoop

129M

11B

K/W

Sectorgemiddelde

16.439

35.733

EPS

0.91

Dividendrendement

7.85

Winstmarge

36.702

Werknemers

82,878

EBITDA

-881M

1.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+32.62% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

7.85%

3.13%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

121B

Vorige openingsprijs

45.08

Vorige sluitingsprijs

47.18

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Sanofi Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 sep 2025, 08:58 UTC

Belangrijke Marktbewegers

Sanofi Shares Sink as Experimental Drug Results Disappoint

31 jul 2025, 06:00 UTC

Winsten

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

22 jul 2025, 12:03 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion -- Update

22 jul 2025, 05:56 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion

5 sep 2025, 08:24 UTC

Marktinformatie

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 sep 2025, 06:55 UTC

Marktinformatie

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

6 aug 2025, 05:02 UTC

Acquisities, Fusies, Overnames

Sanofi Completes the Acquisition of Vigil Neuroscience

6 aug 2025, 05:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Marktinformatie
Winsten

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Marktinformatie
Winsten

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 jul 2025, 05:30 UTC

Winsten

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Business Operating Profit EUR2.46B

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Adj EPS EUR1.59

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Net Pft EUR3.94B

31 jul 2025, 05:30 UTC

Winsten

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 jul 2025, 05:30 UTC

Winsten

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 jul 2025, 05:30 UTC

Winsten

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 jul 2025, 05:30 UTC

Winsten

Sanofi 2Q Sales EUR9.99B

31 jul 2025, 05:30 UTC

Winsten

Sanofi Backs 2025 EPS Adj View

31 jul 2025, 05:30 UTC

Winsten

Sanofi Narrows 2025 Sales View

31 jul 2025, 05:30 UTC

Winsten

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

22 jul 2025, 08:45 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk

Peer Vergelijking

Prijswijziging

Sanofi Prognose

Koersdoel

By TipRanks

32.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 61.67 USD  32.62%

Hoogste 67 USD

Laagste 58 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sanofi - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technische score

By Trading Central

51.665 / 52.38Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat